Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Blood (2025) 146 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2025-4598

Published: 2025

Journal Articles

Real-world patient characteristics, treatment patterns, and outcomes among relapsed/refractory multiple myeloma patients receiving talquetamab-tgvs

Darren Pan, Eric Chinaeke, Yi-Hsuan Liu, Oluwabunmi Emidio, Caleb Paydar, Angele Kotomale, Monica Ahlquist, Bruce Feinberg, Agne Paner-Straseviciute, Jessica Fowler, Xinke Zhang

Blood (2025) 146 (Supplement 1): 2818.

https://doi.org/10.1182/blood-2025-2818

Published: 2025

Journal Articles

Impact of low disease burden on the safety and efficacy of BCMA CAR-T in patients with Relapsed/Refractory multiple myeloma

Kevin Reyes, Tanya Jindal, Sireesha Asoori, Chiung-Yu Huang, Darren Pan, Anupama Kumar, Shagun Arora, Alfred Chung, Peter Sayre, Jeffrey Lee Wolf, Ajai Chari, Thomas Martin, Jodi Lipof

Blood (2025) 146 (Supplement 1): 2202.

https://doi.org/10.1182/blood-2025-2202

Published: 2025

Journal Articles

Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients

Darren Pan, Jihong Song, Eva Duvalyn, Samantha Shenoy, Chiung-Yu Huang, Anupama Kumar, Jodi Lipof, Alfred Chung, Jeffrey Lee Wolf, Thomas Martin, Shagun Arora, Peter Sayre, Ajai Chari

Blood (2025) 146 (Supplement 1): 5760.

https://doi.org/10.1182/blood-2025-5760

Published: 2025

Journal Articles

Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy

Kevin Reyes, Jodi Lipof, Serena Kwek, Averey Lea, Matthew Clark, Lisa Dunn, Ruixin Sun, Emily Mohler, Jane Greenaway, Darren Pan, Anupama Kumar, Alfred Chung, Peter Sayre, Shagun Arora, Jeffrey Lee Wolf, Thomas Martin, Ajai Chari, David Oh

Blood (2025) 146 (Supplement 1): 3916.

https://doi.org/10.1182/blood-2025-3916

Published: 2025

Journal Articles

Outcomes of elderly patients with newly diagnosed multiple myeloma (NDMM): A retrospective comparison of daratumumab-based induction versus autologous stem cell transplant (autoSCT)

Kwan-Keat Ang, Arvind Suresh, Meryl Colton, Anupama Kumar, Darren Pan, Jodi Lipof, Shagun Arora, Alfred Chung, Peter Sayre, Jeffrey Lee Wolf, Thomas Martin, Ajai Chari

Blood (2025) 146 (Supplement 1): 6346.

https://doi.org/10.1182/blood-2025-6346

Published: 2025

Journal Articles

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4042.

https://doi.org/10.1182/blood-2025-4042

Published: 2025

Journal Articles

Impact of maintenance strategies post-autologous stem cell transplant in patients with newly diagnosed multiple myeloma and high-risk cytogenetic abnormalities

Arvind Suresh, Kwan-Keat Ang, Jodi Lipof, Darren Pan, Anupama Kumar, Shagun Arora, Peter Sayre, Jeffrey Lee Wolf, Thomas Martin, Ajai Chari, Alfred Chung

Blood (2025) 146 (Supplement 1): 2805.

https://doi.org/10.1182/blood-2025-2805

Published: 2025

Journal Articles

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Blood (2025) 146 (17): 2063–2072.

https://doi.org/10.1182/blood.2025029773

Published: 2025

Includes: Supplemental data

Journal Articles

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation

Zachary M Avigan, Saoirse Bodnar, Darren Pan, Adolfo Aleman, Joshua Richter, Larysa J Sanchez, Cesar Rodriguez, Adriana Rossi, Shambavi Richard, Hearn Jay Cho, Sundar Jagannath, Samir Parekh, Santiago Thibaud

Blood (2024) 144 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2024-202725

Published: 2024

Journal Articles

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Blood (2023) 142 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2023-181936

Published: 2023

Journal Articles

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Darren Pan, Tarek H. Mouhieddine, Weijia Fu, Erin Moshier, Samir Parekh, Sundar Jagannath, Adriana C Rossi, Joshua Richter, Cesar Rodriguez, Larysa J Sanchez, Santiago Thibaud, Hearn Jay Cho, Shambavi Richard

Blood (2023) 142 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2023-177749

Published: 2023

Journal Articles

Outcomes with Panobinostat in Heavily Pretreated Multiple Myeloma Patients

Darren Pan, Tarek H. Mouhieddine, Ranjan Upadhyay, Nicole Casasanta, Angela Lee, Nicole Zubizarreta, Erin Moshier, Joshua Richter

Blood (2022) 140 (Supplement 1): 12483–12484.

https://doi.org/10.1182/blood-2022-159806

Published: 2022

Journal Articles

Real-World Multiple Myeloma Front-Line Treatment and Outcomes By Transplant in the United States

Joshua Richter, Darren Pan, Taylor Salinardi, Megan S. Rice

Blood (2022) 140 (Supplement 1): 7187–7188.

https://doi.org/10.1182/blood-2022-157812

Published: 2022

Journal Articles

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Oliver Van Oekelen, Tarek H. Mouhieddine, Darren Pan, Megan Metzger, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Alessandro Lagana, Shambavi Richard, Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 2704.

https://doi.org/10.1182/blood-2021-152243

Published: 2021

Journal Articles

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Tarek H. Mouhieddine, Oliver Van Oekelen, Darren Pan, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Santiago Thibaud, Larysa Sanchez, Shambavi Richard, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 821.

https://doi.org/10.1182/blood-2021-151585

Published: 2021

Journal Articles

Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance

Larysa Sanchez, MD, Erin Moshier, MS, Alexander Coltoff, MD, Ali Mustafa, MD, Darren Pan, MD BS, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Deepu Madduri, MD, Samir Parekh, MD, Shambavi Richard, MD, Joshua Richter, MD, Ajai Chari, MD

Blood (2019) 134 (Supplement_1): 1779.

https://doi.org/10.1182/blood-2019-128441

Published: 2019

Journal Articles

Race, Socioeconomic Status, and Time to Transplantation in Multiple Myeloma

Darren Pan, MD BS, Alexander Coltoff, MD, Umut Ozbek, PhD, Jung-Yi Lin, MS, Solmaz Afshar, BSc, Amir Steinberg, MD

Blood (2018) 132 (Supplement 1): 2263.

https://doi.org/10.1182/blood-2018-99-110316

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Short survival with BCMA and GPRC5D dual antigen exposed relapsed myeloma- an international myeloma working group immunotherapy database analysis

Real-world patient characteristics, treatment patterns, and outcomes among relapsed/refractory multiple myeloma patients receiving talquetamab-tgvs

Impact of low disease burden on the safety and efficacy of BCMA CAR-T in patients with Relapsed/Refractory multiple myeloma

Sequential BCMA- and GPRC5D-targeted bispecific antibody therapy in multiple myeloma: Real-world outcomes and first report of dual bispecific antibody-refractory patients

Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy

Outcomes of elderly patients with newly diagnosed multiple myeloma (NDMM): A retrospective comparison of daratumumab-based induction versus autologous stem cell transplant (autoSCT)

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Impact of maintenance strategies post-autologous stem cell transplant in patients with newly diagnosed multiple myeloma and high-risk cytogenetic abnormalities

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation

Early and Consistent CRS Detection Using Wearable Device for Remote Patient Monitoring Following CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM): Early Results of an Investigator-Initiated Trial

Outcomes after CAR T Cells in Multiple Myeloma Patients with Extramedullary and Paramedullary Disease

Outcomes with Panobinostat in Heavily Pretreated Multiple Myeloma Patients

Real-World Multiple Myeloma Front-Line Treatment and Outcomes By Transplant in the United States

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance

Race, Socioeconomic Status, and Time to Transplantation in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only